Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer

被引：0
|
作者：
Ni, M. [1 ]
Zhou, L. [1 ]
Lu, Y. [2 ]
Zhang, L. [2 ,3 ]
Li, X. [4 ]
Chen, M. [2 ]
Yang, A. [5 ]
Zhang, L. [2 ,3 ]
Xu, F. [1 ]
Yuan, Z. [1 ]
Wang, S. [1 ]
Shi, Y. [1 ]
An, X. [5 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Tumor Hosp, Guangxi, Peoples R China
[3] Puning Peoples Hosp, Puning, Peoples R China
[4] Guangzhou Panyu Cent Hosp, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Breast Oncol, Ctr Canc, Collaborat Innovat Ctr Canc Med,State Key Lab Onc, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.198
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
63P
引用
收藏
页码：S1490 / S1490
页数：1
相关论文
共 50 条
  • [21] Advances in chemotherapy for HER2-negative metastatic breast cancer
    Mukai, Hirofumi
    Ito, Mayuko
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [22] Results of a phase Ib study investigating durvalumab in combination with eribulin in patients with metastatic HER2-negative breast cancer and recurrent ovarian cancer.
    Landry, Chrystal Ann
    Ru, Meng
    Hickson, Christopher
    Klein, Paula
    Fasano, Julie
    Bhardwaj, Aarti
    Shapiro, Charles L.
    Irie, Hanna
    Shao, Theresa
    Selkridge, Isaiah
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
    Pernas, Sonia
    Martin, Miguel
    Kaufman, Peter A.
    Gil-Martin, Marta
    Gomez Pardo, Patricia
    Lopez-Tarruella, Sara
    Manso, Luis
    Ciruelos, Eva
    Alejandro Perez-Fidalgo, Jose
    Hernando, Cristina
    Ademuyiwa, Foluso O.
    Weilbaecher, Katherine
    Mayer, Ingrid
    Pluard, Timothy J.
    Martinez Garcia, Maria
    Vahdat, Linda
    Perez-Garcia, Jose
    Wach, Achim
    Barker, Debra
    Fung, Samson
    Romagnoli, Barbara
    Cortes, Javier
    LANCET ONCOLOGY, 2018, 19 (06): : 812 - 824
  • [24] Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: Real life experience
    Kovalenko, E.
    Manzyuk, L.
    Gorbunova, V.
    Kolyadina, I.
    Bolotina, L.
    Zhilyaeva, L.
    Ponomarenko, D.
    Karabina, E.
    Mukhametshina, G.
    Khasanova, A.
    Ekaterina, R.
    Safarova, A.
    Manikhas, A.
    Volkonsky, M.
    Kramskaya, L.
    Karandeeva, T.
    Suslova, I.
    Popova, N.
    Evstigneeva, I.
    Shumskaya, I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S59 - S59
  • [25] EFFICACY AND SAFETY OF ERIBULIN IN COMBINATION WITH TRASTUZIMAB IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS: REAL LIFE EXPERIENCE
    Kovalenko, Elena Igorevna
    Manzyuk, Ludmila
    Gorbunova, Vera Andreevna
    Bolotina, Larisa Vladimirovna
    Zhilyaeva, Larisa
    Ponomarenko, Dmitry Mikhailovich
    Karabina, Elena Vladimirovna
    Mukhametshina, Guzel Zinurovna
    Khasanova, Alfia Irekovna
    Evstigneeva, Irina Vladimirovna
    BREAST, 2017, 36 : S54 - S54
  • [26] Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer?
    Rodriguez Garces, Maria Yeray
    Fernandez Madrigal, Laura
    Morales Pancorbo, David
    Bayo, Juan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).
    Kim, Se Hyun
    Suh, Koung Jin
    Im, Seock-Ah
    Lee, Kyung-Hun
    Kim, Min Hwan
    Sohn, Joohyuk
    Park, Yeon Hee
    Kim, Ji-Yeon
    Jeong, Jae Ho
    Lee, Kyoung Eun
    Choi, In Sil
    Park, Kyong Hwa
    Kim, Hee Jun
    Cho, Eun Kyung
    Park, So Yeon
    Kim, Milim
    Kim, Jee Hyun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Combination treatment for HER2-negative, advanced breast cancer
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (04) : 315 - 315
  • [29] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wang, Wei
    Lei, Wenqian
    Fang, Ziru
    Jiang, Ruiyuan
    Wang, Xiaojia
    BMC CANCER, 2024, 24 (01)
  • [30] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wei Wang
    Wenqian Lei
    Ziru Fang
    Ruiyuan Jiang
    Xiaojia Wang
    BMC Cancer, 24
12345